Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

Share Price is delayed by 15 minutes
Get Live Data
0.19    -0.002 (-1.05%)
Bid:
0.18
Ask:
0.20
Spread: 0.02 (11.111%)
Market Cap: £8.07m
OBD Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biodyn Share Chart

Holding(s) in Company

8 Dec 2016 09:31

RNS Number : 3213R
Oxford BioDynamics PLC
08 December 2016
 
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

OXFORD BIODYNAMICS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

AROUL SELVAM RAMADASS

 

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

06 DEC 2016

6. Date on which issuer notified:

07 DEC 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00BD5H8572

6,509,145

6,509,145

5,431,744

5,431,744

6.3%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

5,431,744

6.3%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Aroul Ramadass (CTO)

Oxford BioDynamics Plc

15. Contact telephone number:

+44 (0) 1865 518 910

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEANAPEAPKFEF
Date   Source Headline
15th Apr 20267:00 amRNSBoard Appointment
30th Mar 20264:07 pmRNSHolding(s) in Company
20th Mar 202612:03 pmRNSHolding(s) in Company
3rd Mar 20269:30 amRNS-ROBD to present at PMWC 2026
17th Feb 20267:00 amRNSChange of Nominated Adviser
27th Jan 202612:52 pmRNSHolding(s) in Company
26th Jan 202612:10 pmRNSResult of AGM
26th Jan 20267:00 amRNSBoard Change
22nd Dec 202511:00 amRNSPublication of 2025 Annual Report
22nd Dec 202511:00 amRNSPublication of 2025 Annual Report
16th Dec 20257:00 amRNSPreliminary Results and Notice of AGM
9th Dec 202512:40 pmRNSNotice of Results
3rd Dec 20257:00 amRNSStatement re share price, update on EpiSwitch PSE
25th Nov 20252:05 pmRNSHolding(s) in Company
12th Nov 20257:00 amRNSHolding(s) in Company
11th Nov 20252:12 pmRNSHolding(s) in Company
11th Nov 20252:11 pmRNSHolding(s) in Company
11th Nov 20252:10 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSPDMR Dealing / Grant of Share Options
7th Nov 202511:32 amRNSResult of General Meeting/PDMR Dealings
22nd Oct 20257:00 amRNSFundraising, Posting of Circular & Notice of GM
14th Oct 20257:00 amRNS-ROBD in New Report on NHS Prostate Cancer Screening
8th Oct 20257:00 amRNSOBD and UEA develop test for Chronic Fatigue
10th Sep 20257:00 amRNSHolding(s) in Company
4th Sep 202510:00 amRNS-RStudy confirms clinical utility of EpiSwitch CiRT
13th Aug 20257:00 amRNSCollaboration with Google Cloud
18th Jul 20253:11 pmRNSHolding(s) in Company
17th Jul 20257:01 amRNS-RGenomeWeb to host joint Agilent/OBD presentation
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20255:20 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNS-RPfizer study on EpiSwitch biomarkers
1st Jul 20253:00 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSInterim Results
27th Jun 20251:30 pmRNSHolding(s) in Company
9th May 20257:00 amRNS-ROBD’s Oxford Lab accredited by UKAS
10th Apr 20254:10 pmRNSDirector/PDMR Shareholding
2nd Apr 20257:00 amRNSPDMR Dealing
28th Mar 202510:35 amRNSResult of AGM
17th Mar 20257:00 amRNSBoard Changes
14th Mar 20255:25 pmRNSHolding(s) in Company
13th Mar 20257:00 amRNS-RExpansion of OBD/Bupa UK insurance partnership
5th Mar 20254:00 pmRNSPublication of 2024 Annual Report
3rd Mar 20257:00 amRNSPDMR Dealing / Grant of Share Options
28th Feb 20257:00 amRNSPreliminary Results and Notice of AGM
21st Feb 202510:00 amRNSNotice of Preliminary Results
17th Feb 20251:07 pmRNSHolding(s) in Company
12th Feb 20254:48 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNS-ROBD partners with Regina Maria in Romania
10th Feb 202512:09 pmRNSHolding(s) in Company
6th Feb 20251:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.